In nephrectomized uremic rats receiving a hyperphosphatemia-inducing diet, Paricalcitol treatment yielded total serum calcium of 10.1 ± 0.27 mg/dL, with the compound effect assessed versus NX-vehicle. In rats with guidewire-induced endothelial injury, the intima/media ratio was 0.17 (0.07, 0.29) with Paricalcitol and 0.18 (0.11, 0.40) with Injury Vehicle. In mice with catheter implantation, peritoneal membranes were thicker in the PDF-treated group than in the Paricalcitol-treated group. [1,2,3]
Serum Calcium in Uremic Rats
Animal study · male, Sprague-Dawley rats; 5/6 nephrectomized (NX) uremic rats; n = 8–11 per group [1]
Male Sprague-Dawley nephrectomized uremic rats receiving a hyperphosphatemia-inducing diet were treated with Paricalcitol at 0.33 μg/kg i.p. Total serum calcium was 10.1 ± 0.27 mg/dL, with the compound effect assessed versus NX-vehicle.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- 3 times/week, for two weeks
- Vehicle
- 5% ethanol +95% propylene glycol, 0.4 mL/kg
- Paricalcitol 0.33 μg/kg
- Model: male, Sprague-Dawley rats; 5/6 nephrectomized (NX) uremic rats; n = 8–11 per group
Methods and source locations
Compound reported in the paper: Paricalcitol
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Methods > 2.2. Subtotally Nephrectomized Rats (S3, S4, S5); 3. Results (S49, S54, S56); Figure 2 legend (S76); Figure 4 legend (S89); Table 1 legend (S110, S111); Table 1 (T1.h1, T1.r4)
Total serum Ca (mg/dL): Total serum Ca (mg/dL); comparator: 5/6 NX-vehicle — Figure 4 legend (S89); Table 1 legend (S110, S111); Table 1 (T1.h1, T1.r4)
Paricalcitol 0.33 μg/kg · Figure 4 legend (S89); Table 1 legend (S111); Table 1 (T1.h1, T1.r4)
Paricalcitol and Intima/Media Ratio After Vascular Injury
Animal study · female 2-month-old Wistar Kyoto rats [2]
Female Wistar Kyoto rats underwent endothelial denudation through guidewire injury and received Paricalcitol intraperitoneally at 750 ng/kg of body weight every other day. The intima/media ratio was 0.17 (0.07, 0.29) for Injury Paricalcitol versus 0.18 (0.11, 0.40) for Injury Vehicle, with a p value of 0.41.
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- every other day; starting immediately after the intervention for 2 weeks
- Vehicle
- alcohol 20% v/v, propylene glycol and purified water
- Paricalcitol 750 ng/kg of body weight
- Model: female 2-month-old Wistar Kyoto rats
Methods and source locations
Compound reported in the paper: Paricalcitol
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Paricalcitol, Intimal Hyperplasia and Stenosis Secondary to Endothelial Injury (S2); 4. Materials and Methods > 4.2. Animal Model (S24); Table 1 (T1.h1, T1.r2)
Intima/media ratio: Intima/media ratio; comparator: Injury Vehicle — Table 1 (T1.h1, T1.r2)
Paricalcitol 750 ng/kg of body weight · 4. Materials and Methods > 4.2. Animal Model (S24); Table 1 (T1.h1, T1.r2)
Peritoneal Membrane Thickness in Mice
Animal study · Female C57BL/6 mice; n = 11 [3]
Female mice with catheter implantation received Paricalcitol at 0.3 µg/kg/week, instilled daily into the peritoneal cavity for 30 days. Peritoneal membranes were thicker in the PDF-treated group than in the paricalcitol-treated group.
Conditions shared by the study groups
- Route
- instilled daily into the mouse peritoneal cavity
- Treatment course
- daily into the mouse peritoneal cavity for 30 days
- Vehicle
- PDF
- Paricalcitol 0.3 µg/kg/week (0.86 ng/mouse/day)
- Model: Female C57BL/6 mice; n = 11
Methods and source locations
Compound reported in the paper: Paricalcitol
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Animals and surgery (S2, S3, S13, S14); Materials and Methods > Paricalcitol treatment (S19); Materials and Methods > Histological analyses and immunofluorescence (S22); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S60, S62)
thickness of peritoneal membrane: thickness of peritoneal membrane; comparator: PDF group; n = 10 — Materials and Methods > Paricalcitol treatment (S19); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S60, S62)
Paricalcitol 0.3 µg/kg/week (0.86 ng/mouse/day) · Materials and Methods > Paricalcitol treatment (S19); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S62)